A Study Of The Selective PKC-β Inhibitor MS- 553

Stopped The study is terminated due to major protocol revisions. A new study in CLL patients is planned.

Conditions

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma
• Aggressive Lymphoma

Interventions

• DRUG: MS-553
• DRUG: MS-553
• DRUG: acalabrutinib
• DRUG: venetoclax
• DRUG: Rituximab
• DRUG: obinutuzumab

Sponsor

MingSight Pharmaceuticals, Inc